Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Apply
Osimertinib & Tegavivint
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step